Evidence map›Paper›PMID 32703744›Full record

ArticleVaccine2020

Modeling the potential impact of administering vaccines against Clostridioides difficile infection to individuals in healthcare facilities.

Damon J A Toth, Lindsay T Keegan, Matthew H Samore, Karim Khader, Justin J O'Hagan, Holly Yu, Alvaro Quintana, David L Swerdlow

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Addressing Unmet Needs inCurrent medicinal chemistry · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Modeling transmission of pathogens in healthcare settings.Current opinion in infectious diseases · 2021
    Review
  7. Transmission Dynamics of Clostridioides difficile in 2 High-Acuity Hospital Units.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Damon J A TothDepartment of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA; Department of Internal Medicine (Epidemiology), University of Utah, Salt Lake City, UT, USA. Electronic address: Damon.Toth@hsc.utah.edu.
Lindsay T KeeganDepartment of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA; Department of Internal Medicine (Epidemiology), University of Utah, Salt Lake City, UT, USA.
Matthew H SamoreDepartment of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA; Department of Internal Medicine (Epidemiology), University of Utah, Salt Lake City, UT, USA. Electronic address: Matthew.Samore@hsc.utah.edu.
Karim KhaderDepartment of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA; Department of Internal Medicine (Epidemiology), University of Utah, Salt Lake City, UT, USA.
Justin J O'HaganDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Holly YuPfizer, Inc., USA.
Alvaro QuintanaPfizer, Inc., USA.
David L SwerdlowPfizer, Inc., USA.
University of Utah · USPfizer (United States) · USCenters for Disease Control and Prevention · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundA vaccine against Clostridioides difficile infection (CDI) is in development. While the vaccine has potential to both directly protect those vaccinated and mitigate transmission by reducing environmental contamination, the impact of the vaccine on C. difficile colonization remains unclear. Consequently, the transmission-reduction effect of the vaccine depends on the contribution of symptomatic CDI to overall transmission of C. difficile.

methodsWe designed a simulation model of CDI among patients in a network of 10 hospitals and nursing homes and calibrated the model using estimates of transmissibility from whole genome sequencing studies that estimated the fraction of CDI attributable to transmission from other CDI patients. We assumed the vaccine reduced the rate of progression to CDI among carriers by 25-95% after completion of a 3-dose vaccine course administered to randomly chosen patients at facility discharge. We simulated the administration of this vaccination campaign and tallied effects over 5 years.

resultsWe estimated 30 times higher infectivity of CDI patients compared to other carriers. Simulations of the vaccination campaign produced an average reduction of 3-16 CDI cases per 1000 vaccinated patients, with 2-11 of those cases prevented among those vaccinated and 1-5 prevented among unvaccinated patients.

conclusionsOur findings demonstrate potential for a vaccine against CDI to reduce transmissions in healthcare facilities, even with no direct effect on carriage susceptibility. The vaccine's population impact will increase if received by individuals at risk for CDI onset in high-transmission settings.

Indexed as

Clostridioides difficileClostridium InfectionsCross InfectionVaccinesClostridioidesDelivery of Health CareHumansVaccinesClostridioides difficileHealthcare-associated infectionMathematical modelTransmissionVaccines

Identifiers

PMID32703744
PMCPMC7898464
OpenAlexW3044566928

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.